Overview

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults because Takeda did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

This technology appraisal guidance is now being reviewed as brentuximab vedotin for untreated advanced Hodgkin lymphoma [ID6334].

  • National Institute for Health and Care Excellence (NICE)